Aurora Diagnostics, the leading independent specialized laboratory company focused on anatomic pathology and cancer diagnostics in the United States, announced today that it has named Catherine Dumur, Ph.D., Director of Molecular and Next Generation Sequencing (NGS) Development.
“Dr. Dumur brings more than 15 years of experience in molecular diagnostics for oncology to Aurora Diagnostics,” said F. Michael Walsh, Chief Medical Officer of Aurora Diagnostics. “With a proven track record and extensive research in cancer-specific tissue analysis, Dr. Dumur will be a great asset to our doctors and medical partners, and will help ensure we remain a leader in anatomic pathology and cancer diagnostics.”
Before joining Aurora, Dr. Dumur served as the Associate Director of Molecular Diagnostics in the Pathology Department at Virginia Commonwealth University. Dr. Dumur first joined VCU in Richmond, Virginia, as a teaching assistant and held various roles in the Pathology Department.
At Aurora Diagnostics, Dr. Dumur is responsible for development and ongoing performance of NGS molecular diagnostics assays, proficiency testing, quality control, quality improvement programs, and for signing out clinical cases. She directs an experienced technical staff to deliver NGS assays for hereditary predictive risk and solid tumor cancer tests.
“I am thrilled to be a part of a team that is on the leading edge of pathology and cancer diagnostics,” Dr. Dumur said. “I look forward to working with the talented team at Aurora Diagnostics.”
About Aurora Diagnostics
Aurora Diagnostics is a leading independent pathology services and cancer diagnostics company, offering integrated diagnostic and personalized medicine consultations and information technology solutions to physicians and hospital systems. Our pathologists provide diagnostic opinions and work collaboratively with referring physicians to determine appropriate patient treatment options. We also provide services to pharmaceutical companies and other research entities to support their efforts to develop new cancer treatments.
Aurora Diagnostics operates 26 community-based pathology practices with over 160 board-certified pathologists. We provide services to a broad array of physician specialists, including dermatologists, obstetricians and gynecologists, family practitioners, gastroenterologists, urologists, general surgeons and oncologists.
Our client-centric approach to providing diagnostic services is driven by our belief that the practice of medicine and the delivery of healthcare are both personal and best delivered locally. With our extensive pathology expertise, we are able to support comprehensive integrated approaches to patient care. For additional information regarding Aurora Diagnostics, please visit www.auroradx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005477/en/Business Wire
Last updated on: 10/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.